Nov . 19, 2026 16:40 Back to list
Sexually transmitted infections (STIs) remain an important concern in global healthcare. Different pathogens can cause similar clinical symptoms, while some infections may develop without obvious signs. As a result, identifying the specific infectious agents is essential for accurate clinical assessment and appropriate patient management.
Conventional testing approaches may require separate assays for different pathogens, increasing laboratory workload and testing complexity. With advances in molecular diagnostics, multiplex PCR technology provides a more integrated approach by enabling the detection of multiple genetic targets within a coordinated testing workflow.
The Cowingene STI Multiplex Pro Detection Kit-STI21 (Liquid) is developed for molecular STI detection using PCR-based technology. Designed around a multiplex detection concept, this product aims to support broader pathogen identification and efficient laboratory testing.
As a specialized manufacturer of molecular POCT in vitro diagnostic reagents, Cowin Gene focuses on developing innovative diagnostic products that help healthcare professionals improve testing efficiency, accessibility, and convenience.

The value of a multiplex molecular diagnostic kit lies in its ability to address multiple detection requirements through one integrated assay design.
STIs can be associated with different bacterial, viral, and other infectious pathogens. Testing for only one pathogen may not provide sufficient information when several possible infections need to be considered.
The Cowingene STI Multiplex Pro Detection Kit-STI21 is positioned as a multi-target molecular diagnostic solution. Its STI21 designation represents the product's detection panel identity, with the exact target coverage determined by its validated product specifications.
Compared with separate single-target testing approaches, multiplex detection may offer several advantages.
Multiple Target Identification
A multiplex assay is designed to detect multiple pathogen-related genetic targets within a coordinated testing system.
More Comprehensive Testing Information
Multi-target detection can help healthcare professionals obtain broader laboratory information when evaluating potential STI infections.
Improved Testing Workflow
Combining multiple targets within one validated assay may reduce the need for separate testing procedures and simplify laboratory workflow management.
Support for Coinfection Assessment
Depending on the assay design and specimen requirements, multiplex testing may help identify more than one target in the same clinical sample.
These characteristics make multiplex molecular diagnostics an important development direction in modern infectious disease testing.
Polymerase Chain Reaction (PCR) is widely used in molecular diagnostics because it amplifies specific genetic sequences, allowing targeted pathogen-related nucleic acids to be detected.
In multiplex PCR testing, multiple target sequences are evaluated within the same reaction system or coordinated assay workflow, depending on the product design.
Several technical characteristics make this approach valuable for STI diagnostics.
PCR assays use specific primers and, where applicable, probes to recognize selected genetic sequences. This allows the testing system to identify the targets included in its validated panel.
PCR amplification helps detect target genetic material that may be present at relatively low concentrations. The actual analytical sensitivity depends on the assay design, sample quality, and validation results.
Multiplex technology can support the detection of multiple infectious targets within an integrated testing approach, helping laboratories manage complex testing requirements.
Validated molecular assays provide defined result interpretation procedures, including applicable controls and reporting criteria. This helps support consistent testing and quality management.
For laboratories seeking molecular STI testing solutions, the combination of PCR technology and multiplex detection provides an efficient approach to pathogen identification.
Besides detection technology, reagent presentation is another important consideration when selecting a molecular diagnostic product.
The Cowingene STI Multiplex Pro Detection Kit-STI21 uses a liquid reagent format. This presentation is designed for use within the product's specified molecular testing workflow.
The liquid format can offer practical handling characteristics:
Convenient Reagent Preparation
Liquid reagents provide a defined formulation that can be handled according to the manufacturer's preparation and dispensing instructions.
Workflow Compatibility
The reagent format is designed to work within the validated testing procedure and should be used with the specified instruments and compatible sample preparation methods.
Standardized Handling
Following established reagent handling procedures helps laboratories maintain consistent testing conditions.
Quality Control Management
Proper storage, transportation, and handling are essential for maintaining reagent quality and reliable assay performance.
The specific storage temperature, shelf life, reagent preparation steps, and transportation requirements should always follow the official instructions for use.
A standardized molecular testing workflow is essential for reliable pathogen detection. Although individual procedures depend on the specific assay, a typical PCR-based STI testing process includes several stages.
Stage 1: Specimen Collection
Clinical samples should be collected according to the validated specimen types and collection instructions. Proper sample collection and handling are important for maintaining specimen quality.
Stage 2: Nucleic Acid Extraction
Depending on the assay design, nucleic acids may need to be extracted from the specimen before molecular amplification.
Stage 3: Reagent Preparation
The liquid reagents should be prepared according to the manufacturer's instructions. Correct reagent handling and preparation help maintain testing consistency.
Stage 4: Multiplex PCR Detection
The prepared reaction is processed using a compatible PCR instrument. The assay detects its designated genetic targets according to the validated testing methodology.
Stage 5: Result Interpretation
The final results are interpreted according to the manufacturer's reporting criteria and relevant clinical guidelines. Positive molecular results indicate the detection of targeted nucleic acid sequences and should be evaluated by qualified healthcare professionals.
A well-defined testing process helps laboratories improve operational consistency and manage molecular diagnostic procedures more efficiently.
Multiplex STI diagnostic products can support different testing environments where identifying multiple infectious targets is important.
Hospital laboratories handle diverse clinical testing requirements. Multiplex PCR diagnostic kits can help support pathogen identification through an integrated molecular testing workflow.
Specialized laboratories may require flexible molecular diagnostic products that cover multiple pathogen targets and support standardized testing procedures.
STI testing is an important part of sexual and reproductive healthcare. Molecular detection can provide useful laboratory information to support professional clinical evaluation.
Facilities involved in infectious disease testing can benefit from molecular methods that support specific pathogen identification and structured result reporting.
For international distributors and medical product suppliers, STI multiplex detection kits provide an additional category within the growing molecular diagnostics product portfolio.
The intended use, clinical indications, and regulatory authorization of each product should be confirmed before implementation in a particular market.
Behind every molecular diagnostic product is a combination of technical expertise, reagent development, manufacturing capabilities, and continuous innovation.
Cowin Gene is a young and dynamic company specializing in the development and manufacturing of molecular POCT in vitro diagnostic reagents.
Its product development strategy focuses on making molecular testing more efficient, convenient, and accessible.
Rapid Detection Time
Cowin Gene's molecular POCT products emphasize efficient detection workflows, helping healthcare professionals obtain diagnostic information in a timely manner.
Easy Operation Procedure
Convenient operating procedures are an important consideration in product development. Standardized workflows can help clinicians and laboratory personnel perform molecular testing more efficiently.
High-Sensitivity Detection Performance
The company focuses on high-sensitivity detection performance through PCR-based molecular diagnostic technology, addressing the requirements of modern pathogen testing.
Professional Team and Innovation
With a professional team and an innovative development philosophy, Cowin Gene continuously explores molecular diagnostic technologies and develops products for different pathogen detection needs.
Diversified Molecular Diagnostic Portfolio
In addition to STI-related diagnostic products, Cowin Gene's core product portfolio includes PCR-based POCT kits for detecting various viruses, bacteria, and fungi.
This diversified product direction demonstrates the company's commitment to providing practical molecular diagnostic solutions for different healthcare applications.
For clinical laboratories, hospitals, and international distributors, choosing an STI multiplex diagnostic kit requires evaluating several important product characteristics.
Detection Panel Coverage: Confirm the exact 21 targets or detection categories included in the STI21 panel through the official product documentation.
Analytical Performance: Review sensitivity, specificity, limit of detection, cross-reactivity, and other validated performance indicators.
Sample Compatibility: Check the supported specimen types, collection procedures, and nucleic acid extraction requirements.
Instrument Compatibility: Verify whether the kit is compatible with the laboratory's existing PCR equipment.
Reagent Storage: Review storage conditions, transportation requirements, packaging specifications, and shelf life.
Regulatory Compliance: Confirm the product's registration status, applicable certifications, and regulatory requirements in the intended sales market.
A comprehensive evaluation helps buyers select suitable molecular diagnostic products and establish reliable long-term supplier relationships.
It is a PCR-based molecular diagnostic product designed to support multiplex detection of STI-related genetic targets. Its exact detection coverage is defined by the manufacturer's validated product specifications.
Q2: What does STI21 mean?
STI21 is the product's panel designation. Buyers should consult the official product documentation to confirm the exact pathogens and genetic targets included in the detection panel.
Multiplex testing can support the detection of multiple pathogen targets within an integrated testing workflow, potentially improving testing efficiency and reducing the need for separate assays.
Q4: What is the advantage of the liquid reagent format?
Liquid reagents provide a liquid formulation for molecular testing workflows. Their preparation, storage, and handling requirements depend on the specific product instructions.
The product belongs to Cowin Gene's PCR-based molecular diagnostic product range. PCR technology amplifies specific genetic sequences to support pathogen identification.
Qualified hospitals, clinical laboratories, diagnostic institutions, and authorized healthcare facilities may use validated STI molecular detection products according to their intended use.
The Cowingene STI Multiplex Pro Detection Kit-STI21 (Liquid) represents a multiplex molecular diagnostic solution designed to support the detection of multiple STI-related targets through PCR-based technology.
By combining a multi-target testing approach with a liquid reagent format, the product addresses important considerations in modern molecular diagnostic workflows.
With its professional technical team, innovation-driven development strategy, and diversified molecular POCT product portfolio, Cowin Gene is committed to advancing accessible and efficient diagnostic technologies.
For healthcare institutions, diagnostic laboratories, and international medical product distributors, Cowin Gene aims to become a trusted partner in the evolving field of molecular diagnostics.
This is the first article
Related PRODUCTS
Meet COWIN GENE at WHX Bangkok 2026!
NewsJun.09,2026Supporting Ebolavirus Surveillance with Real-time PCR Detection
NewsMay.27,20267 Days To Go Until Whx Lagos 2026!
NewsMay.26,2026Cowingene Respiratory Pathogen Panel Pro Detection Kit (Liquid): Advanced Molecular Diagnostics for Respiratory Infections
NewsNov.19,2026Cowingene HPV Genotyping Detection Kit - HPV-40 Panel (Liquid): Comprehensive Molecular Testing with PCR Technology
NewsNov.19,2026